Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Radiopharmaceuticals in Nuclear Medical market report explains the definition, types, applications, major countries, and major players of the Radiopharmaceuticals in Nuclear Medical market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Nordion
Cambridge Isotope Laboratories
Rotem Industries
Bracco Imaging
GE Healthcare (Subsidiary Of General Electric Company)
Lantheus Medical Imaging
Siemens Healthcare
Cardinal Health
Covidien
Ntp Radioisotopes
Urenco Limited
Eczacibasi-Monrol
Taiyo Nippon Sanso Corporation
IBA Group
Fujifilm Holdings Corporation
By Type:
Diagnostic Radiopharmaceuticals
Therapy Radiopharmaceuticals
Enriched Stable Isotopes
By End-User:
Diagnostic Application
Therapeutic Application
Research
Pharmaceutical
Industrial
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Radiopharmaceuticals in Nuclear Medical Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Radiopharmaceuticals in Nuclear Medical Outlook to 2028- Original Forecasts
-
2.2 Radiopharmaceuticals in Nuclear Medical Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Radiopharmaceuticals in Nuclear Medical Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Radiopharmaceuticals in Nuclear Medical Market- Recent Developments
-
6.1 Radiopharmaceuticals in Nuclear Medical Market News and Developments
-
6.2 Radiopharmaceuticals in Nuclear Medical Market Deals Landscape
7 Radiopharmaceuticals in Nuclear Medical Raw Materials and Cost Structure Analysis
-
7.1 Radiopharmaceuticals in Nuclear Medical Key Raw Materials
-
7.2 Radiopharmaceuticals in Nuclear Medical Price Trend of Key Raw Materials
-
7.3 Radiopharmaceuticals in Nuclear Medical Key Suppliers of Raw Materials
-
7.4 Radiopharmaceuticals in Nuclear Medical Market Concentration Rate of Raw Materials
-
7.5 Radiopharmaceuticals in Nuclear Medical Cost Structure Analysis
-
7.5.1 Radiopharmaceuticals in Nuclear Medical Raw Materials Analysis
-
7.5.2 Radiopharmaceuticals in Nuclear Medical Labor Cost Analysis
-
7.5.3 Radiopharmaceuticals in Nuclear Medical Manufacturing Expenses Analysis
8 Global Radiopharmaceuticals in Nuclear Medical Import and Export Analysis (Top 10 Countries)
-
8.1 Global Radiopharmaceuticals in Nuclear Medical Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Radiopharmaceuticals in Nuclear Medical Export by Region (Top 10 Countries) (2017-2028)
9 Global Radiopharmaceuticals in Nuclear Medical Market Outlook by Types and Applications to 2022
-
9.1 Global Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Diagnostic Radiopharmaceuticals Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Therapy Radiopharmaceuticals Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Enriched Stable Isotopes Consumption and Growth Rate (2017-2022)
-
9.2 Global Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Diagnostic Application Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Therapeutic Application Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Research Consumption and Growth Rate (2017-2022)
-
9.2.4 Global Pharmaceutical Consumption and Growth Rate (2017-2022)
-
9.2.5 Global Industrial Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Radiopharmaceuticals in Nuclear Medical Market Analysis and Outlook till 2022
-
10.1 Global Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.2.2 Canada Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.2.3 Mexico Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.3.2 UK Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.3.3 Spain Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.3.4 Belgium Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.3.5 France Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.3.6 Italy Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.3.7 Denmark Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.3.8 Finland Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.3.9 Norway Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.3.10 Sweden Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.3.11 Poland Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.3.12 Russia Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.3.13 Turkey Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.4.2 Japan Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.4.3 India Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.4.4 South Korea Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.4.5 Pakistan Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.4.6 Bangladesh Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.4.7 Indonesia Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.4.8 Thailand Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.4.9 Singapore Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.4.10 Malaysia Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.4.11 Philippines Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.4.12 Vietnam Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.5.2 Colombia Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.5.3 Chile Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.5.4 Argentina Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.5.5 Venezuela Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.5.6 Peru Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.5.7 Puerto Rico Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.5.8 Ecuador Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.6.2 Kuwait Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.6.3 Oman Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.6.4 Qatar Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.6.5 Saudi Arabia Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.6.6 United Arab Emirates Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.7.2 South Africa Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.7.3 Egypt Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.7.4 Algeria Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
-
10.8.2 New Zealand Radiopharmaceuticals in Nuclear Medical Consumption (2017-2022)
11 Global Radiopharmaceuticals in Nuclear Medical Competitive Analysis
-
11.1 Nordion
-
11.1.1 Nordion Company Details
-
11.1.2 Nordion Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Nordion Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
11.1.4 Nordion Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Cambridge Isotope Laboratories
-
11.2.1 Cambridge Isotope Laboratories Company Details
-
11.2.2 Cambridge Isotope Laboratories Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Cambridge Isotope Laboratories Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
11.2.4 Cambridge Isotope Laboratories Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Rotem Industries
-
11.3.1 Rotem Industries Company Details
-
11.3.2 Rotem Industries Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Rotem Industries Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
11.3.4 Rotem Industries Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Bracco Imaging
-
11.4.1 Bracco Imaging Company Details
-
11.4.2 Bracco Imaging Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Bracco Imaging Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
11.4.4 Bracco Imaging Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 GE Healthcare (Subsidiary Of General Electric Company)
-
11.5.1 GE Healthcare (Subsidiary Of General Electric Company) Company Details
-
11.5.2 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
11.5.4 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Lantheus Medical Imaging
-
11.6.1 Lantheus Medical Imaging Company Details
-
11.6.2 Lantheus Medical Imaging Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Lantheus Medical Imaging Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
11.6.4 Lantheus Medical Imaging Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Siemens Healthcare
-
11.7.1 Siemens Healthcare Company Details
-
11.7.2 Siemens Healthcare Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Siemens Healthcare Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
11.7.4 Siemens Healthcare Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Cardinal Health
-
11.8.1 Cardinal Health Company Details
-
11.8.2 Cardinal Health Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Cardinal Health Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
11.8.4 Cardinal Health Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Covidien
-
11.9.1 Covidien Company Details
-
11.9.2 Covidien Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Covidien Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
11.9.4 Covidien Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Ntp Radioisotopes
-
11.10.1 Ntp Radioisotopes Company Details
-
11.10.2 Ntp Radioisotopes Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Ntp Radioisotopes Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
11.10.4 Ntp Radioisotopes Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 Urenco Limited
-
11.11.1 Urenco Limited Company Details
-
11.11.2 Urenco Limited Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 Urenco Limited Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
11.11.4 Urenco Limited Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
11.11.5 Recent Research and Development Strategies
-
11.12 Eczacibasi-Monrol
-
11.12.1 Eczacibasi-Monrol Company Details
-
11.12.2 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
11.12.3 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
11.12.4 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
11.12.5 Recent Research and Development Strategies
-
11.13 Taiyo Nippon Sanso Corporation
-
11.13.1 Taiyo Nippon Sanso Corporation Company Details
-
11.13.2 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
11.13.3 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
11.13.4 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
11.13.5 Recent Research and Development Strategies
-
11.14 IBA Group
-
11.14.1 IBA Group Company Details
-
11.14.2 IBA Group Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
11.14.3 IBA Group Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
11.14.4 IBA Group Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
11.14.5 Recent Research and Development Strategies
-
11.15 Fujifilm Holdings Corporation
-
11.15.1 Fujifilm Holdings Corporation Company Details
-
11.15.2 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
11.15.3 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
11.15.4 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
11.15.5 Recent Research and Development Strategies
12 Global Radiopharmaceuticals in Nuclear Medical Market Outlook by Types and Applications to 2028
-
12.1 Global Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Diagnostic Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Therapy Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Enriched Stable Isotopes Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Diagnostic Application Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Therapeutic Application Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Research Consumption Forecast and Growth Rate (2022-2028)
-
12.2.4 Global Pharmaceutical Consumption Forecast and Growth Rate (2022-2028)
-
12.2.5 Global Industrial Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Radiopharmaceuticals in Nuclear Medical Market Analysis and Outlook to 2028
-
13.1 Global Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.2.2 Canada Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.2.3 Mexico Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.3.2 UK Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.3.3 Spain Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.3.4 Belgium Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.3.5 France Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.3.6 Italy Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.3.7 Denmark Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.3.8 Finland Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.3.9 Norway Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.3.10 Sweden Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.3.11 Poland Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.3.12 Russia Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.3.13 Turkey Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.4.2 Japan Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.4.3 India Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.4.4 South Korea Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.4.8 Thailand Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.4.9 Singapore Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.4.11 Philippines Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.5.2 Colombia Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.5.3 Chile Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.5.4 Argentina Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.5.6 Peru Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.6.3 Oman Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.6.4 Qatar Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.7.2 South Africa Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.7.3 Egypt Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.7.4 Algeria Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Radiopharmaceuticals in Nuclear Medical Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Radiopharmaceuticals in Nuclear Medical
-
Figure of Radiopharmaceuticals in Nuclear Medical Picture
-
Table Global Radiopharmaceuticals in Nuclear Medical Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Radiopharmaceuticals in Nuclear Medical Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Diagnostic Radiopharmaceuticals Consumption and Growth Rate (2017-2022)
-
Figure Global Therapy Radiopharmaceuticals Consumption and Growth Rate (2017-2022)
-
Figure Global Enriched Stable Isotopes Consumption and Growth Rate (2017-2022)
-
Figure Global Diagnostic Application Consumption and Growth Rate (2017-2022)
-
Figure Global Therapeutic Application Consumption and Growth Rate (2017-2022)
-
Figure Global Research Consumption and Growth Rate (2017-2022)
-
Figure Global Pharmaceutical Consumption and Growth Rate (2017-2022)
-
Figure Global Industrial Consumption and Growth Rate (2017-2022)
-
Figure Global Radiopharmaceuticals in Nuclear Medical Consumption by Country (2017-2022)
-
Table North America Radiopharmaceuticals in Nuclear Medical Consumption by Country (2017-2022)
-
Figure United States Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Canada Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Mexico Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Table Europe Radiopharmaceuticals in Nuclear Medical Consumption by Country (2017-2022)
-
Figure Germany Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure UK Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Spain Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Belgium Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure France Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Italy Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Denmark Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Finland Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Norway Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Sweden Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Poland Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Russia Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Turkey Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Table APAC Radiopharmaceuticals in Nuclear Medical Consumption by Country (2017-2022)
-
Figure China Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Japan Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure India Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure South Korea Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Thailand Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Singapore Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Philippines Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Table South America Radiopharmaceuticals in Nuclear Medical Consumption by Country (2017-2022)
-
Figure Brazil Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Colombia Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Chile Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Argentina Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Peru Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Table GCC Radiopharmaceuticals in Nuclear Medical Consumption by Country (2017-2022)
-
Figure Bahrain Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Oman Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Qatar Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Table Africa Radiopharmaceuticals in Nuclear Medical Consumption by Country (2017-2022)
-
Figure Nigeria Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure South Africa Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Egypt Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure Algeria Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Table Oceania Radiopharmaceuticals in Nuclear Medical Consumption by Country (2017-2022)
-
Figure Australia Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Radiopharmaceuticals in Nuclear Medical Consumption and Growth Rate (2017-2022)
-
Table Nordion Company Details
-
Table Nordion Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
Table Nordion Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
Table Nordion Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
Table Cambridge Isotope Laboratories Company Details
-
Table Cambridge Isotope Laboratories Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
Table Cambridge Isotope Laboratories Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
Table Cambridge Isotope Laboratories Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
Table Rotem Industries Company Details
-
Table Rotem Industries Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
Table Rotem Industries Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
Table Rotem Industries Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
Table Bracco Imaging Company Details
-
Table Bracco Imaging Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bracco Imaging Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
Table Bracco Imaging Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
Table GE Healthcare (Subsidiary Of General Electric Company) Company Details
-
Table GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
Table GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
Table GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
Table Lantheus Medical Imaging Company Details
-
Table Lantheus Medical Imaging Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
Table Lantheus Medical Imaging Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
Table Lantheus Medical Imaging Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
Table Siemens Healthcare Company Details
-
Table Siemens Healthcare Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
Table Siemens Healthcare Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
Table Siemens Healthcare Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
Table Cardinal Health Company Details
-
Table Cardinal Health Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
Table Cardinal Health Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
Table Cardinal Health Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
Table Covidien Company Details
-
Table Covidien Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
Table Covidien Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
Table Covidien Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
Table Ntp Radioisotopes Company Details
-
Table Ntp Radioisotopes Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
Table Ntp Radioisotopes Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
Table Ntp Radioisotopes Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
Table Urenco Limited Company Details
-
Table Urenco Limited Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
Table Urenco Limited Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
Table Urenco Limited Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
Table Eczacibasi-Monrol Company Details
-
Table Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
Table Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
Table Taiyo Nippon Sanso Corporation Company Details
-
Table Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
Table Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
Table Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
Table IBA Group Company Details
-
Table IBA Group Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
Table IBA Group Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
Table IBA Group Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
Table Fujifilm Holdings Corporation Company Details
-
Table Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medical Sales, Price, Value and Gross Profit (2017-2022)
-
Table Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medical Main Business and Markets Served
-
Table Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medical Product Portfolio
-
Figure Global Diagnostic Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Therapy Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Enriched Stable Isotopes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Diagnostic Application Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Therapeutic Application Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Research Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Pharmaceutical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Industrial Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Radiopharmaceuticals in Nuclear Medical Consumption Forecast by Country (2022-2028)
-
Table North America Radiopharmaceuticals in Nuclear Medical Consumption Forecast by Country (2022-2028)
-
Figure United States Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Radiopharmaceuticals in Nuclear Medical Consumption Forecast by Country (2022-2028)
-
Figure Germany Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Radiopharmaceuticals in Nuclear Medical Consumption Forecast by Country (2022-2028)
-
Figure China Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Radiopharmaceuticals in Nuclear Medical Consumption Forecast by Country (2022-2028)
-
Figure Brazil Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Radiopharmaceuticals in Nuclear Medical Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Radiopharmaceuticals in Nuclear Medical Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Radiopharmaceuticals in Nuclear Medical Consumption Forecast by Country (2022-2028)
-
Figure Australia Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Radiopharmaceuticals in Nuclear Medical Consumption Forecast and Growth Rate (2022-2028)
-
